246 related articles for article (PubMed ID: 34428831)
1. Clopidogrel versus Ticagrelor in CYP2C19 Loss-of-Function Allele Noncarriers: A Real-World Study in China.
Zhang Y; Zhang Y; Shi X; Lin B; Han J; Wang Y; Yan J; Peng W; Li W; Zheng Z; Lin Y
Thromb Haemost; 2022 May; 122(5):842-852. PubMed ID: 34428831
[TBL] [Abstract][Full Text] [Related]
2. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
[TBL] [Abstract][Full Text] [Related]
3. Net clinical benefit of clopidogrel versus ticagrelor in elderly patients carrying CYP2C19 loss-of-function variants with acute coronary syndrome after percutaneous coronary intervention.
Zhang D; Li P; Qiu M; Liang Z; He J; Li Y; Han Y
Atherosclerosis; 2024 Mar; 390():117395. PubMed ID: 38114408
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Peng W; Zhang Y; Li X; Lin Y
J Cardiovasc Pharmacol; 2023 Feb; 81(2):134-140. PubMed ID: 36410041
[TBL] [Abstract][Full Text] [Related]
5. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS
J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750
[TBL] [Abstract][Full Text] [Related]
6. Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y
Zhang Y; Shi XJ; Peng WX; Han JL; Lin BD; Zhang R; Zhang YN; Yan JL; Wei JJ; Wang YF; Chen SW; Nan N; Fang ZW; Zeng Y; Lin Y
Front Pharmacol; 2020; 11():582929. PubMed ID: 33551797
[No Abstract] [Full Text] [Related]
7. Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
Xi Z; Zhou Y; Zhao Y; Liu X; Liang J; Chai M; Yu Y; Liu W
Cardiovasc Drugs Ther; 2020 Apr; 34(2):179-188. PubMed ID: 32140798
[TBL] [Abstract][Full Text] [Related]
8. Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients.
Claassens DMF; Gimbel ME; Bergmeijer TO; Vos GJA; Hermanides RS; van der Harst P; Barbato E; Morisco C; Tjon Joe Gin RM; de Vrey EA; Heestermans TACM; Jukema JW; von Birgelen C; Waalewijn RA; Hofma SH; den Hartog FR; Voskuil M; Van't Hof AWJ; Asselbergs FW; Mosterd A; Herrman JR; Dewilde W; Mahmoodi BK; Deneer VHM; Ten Berg JM
Int J Cardiol; 2021 Jul; 334():10-17. PubMed ID: 33887342
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes and Sustainability of Using
Lee CR; Sriramoju VB; Cervantes A; Howell LA; Varunok N; Madan S; Hamrick K; Polasek MJ; Lee JA; Clarke M; Cicci JD; Weck KE; Stouffer GA
Circ Genom Precis Med; 2018 Apr; 11(4):e002069. PubMed ID: 29615454
[TBL] [Abstract][Full Text] [Related]
10. Effects of the
Biswas M; Sukasem C; Khatun Kali MS; Ibrahim B
Pharmacogenomics; 2022 Feb; 23(3):207-220. PubMed ID: 35042400
[TBL] [Abstract][Full Text] [Related]
11. High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials.
Sheng XY; An HJ; He YY; Ye YF; Zhao JL; Li S
J Clin Pharm Ther; 2022 Aug; 47(8):1112-1121. PubMed ID: 35396752
[TBL] [Abstract][Full Text] [Related]
12. Risk of major adverse cardiovascular events of
Biswas M; Kali MSK; Biswas TK; Ibrahim B
Platelets; 2021 Jul; 32(5):591-600. PubMed ID: 32664772
[TBL] [Abstract][Full Text] [Related]
13. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Jiang M; You JH
Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
[TBL] [Abstract][Full Text] [Related]
14. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
[TBL] [Abstract][Full Text] [Related]
15. Implementation of CYP2C19 genotyping and clinical outcomes following percutaneous coronary intervention in East Asian patients treated with oral P2Y
Xi Z; Wang Y; Lu Q; Qiu H; Gao Y; Gao A; Gao R
Thromb Res; 2023 Aug; 228():85-93. PubMed ID: 37301117
[TBL] [Abstract][Full Text] [Related]
16. In-hospital outcomes of ticagrelor versus clopidogrel in patients 75 years or older with acute coronary syndrome: findings from the Improving Care for Cardiovascular Disease in China (CCC)-Acute Coronary Syndrome Project.
Yang N; Liu J; Liu J; Hao Y; Smith JSC; Huo Y; Fonarow GC; Ge J; Morgan L; Ma C; Han Y; Zhao D;
Age Ageing; 2022 Nov; 51(11):. PubMed ID: 36413586
[TBL] [Abstract][Full Text] [Related]
17. The contribution of genotype-guided selection of P2Y
Wu Y; Yu D; Zhang L; Wu Y; Shu B; Ma L; Shi T
Eur J Clin Pharmacol; 2023 Sep; 79(9):1249-1259. PubMed ID: 37449992
[TBL] [Abstract][Full Text] [Related]
18. Comparison of effectiveness and safety between ticagrelor and clopidogrel in patients with acute coronary syndrome and on dialysis in Taiwan.
Li YS; Wang SH; Hwang SJ; Yang YH; Hsieh KP
Br J Clin Pharmacol; 2022 Jan; 88(1):145-154. PubMed ID: 34080719
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of
Fu Y; Zhang XY; Qin SB; Nie XY; Shi LW; Shao H; Liu J
Pharmacogenomics; 2020 Jan; 21(1):33-42. PubMed ID: 31849282
[No Abstract] [Full Text] [Related]
20.
Tunehag KR; Thomas CD; Franchi F; Rossi JS; Keeley EC; Anderson RD; Beitelshees AL; Duarte JD; Gong Y; Kerensky RA; McDonough CW; Nguyen AB; Ortega-Paz L; Venkatesh S; Wang Y; Johnson JA; Winterstein AG; Stouffer GA; Angiolillo DJ; Cavallari LH; Lee CR
J Am Heart Assoc; 2024 Jun; 13(12):e033791. PubMed ID: 38874073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
